Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature

Frontiers in Oncology

Oncology

Elena Escalera¹  Jesús Chamorro¹  Víctor Albarrán¹  Diana Isabel Rosero¹  María Gion¹  Eva Guerra¹  Javier Pozas¹  María Fernández Abad¹  María San Román¹  Cristina Saavedra¹  Elena López Miranda¹  Noelia Martínez Jañez¹  Alfonso Cortés¹ 

[1] Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain;

关键词: breast cancer;    BRCA;    germline;    PARP inhibitors;    olaparib;    talazoparib;   

DOI  :  10.3389/fonc.2023.1158981

 received in 2023-02-04, accepted in 2023-04-20,  发布年份 2023

来源: Frontiers

【 摘 要 】

PARP inhibitors are progressively becoming a part of our therapeutic arsenal against BRCA-defective tumors, because of their capacity to induce synthetic lethality in cells with a deficiency in the homologous recombination repair system. Olaparib and talazoparib have been approved for metastatic breast cancer in carriers of germline BRCA mutations, which are found in approximately 6% of patients with breast cancer. We report the case of a patient with metastatic breast cancer, carrier of a germline mutation in BRCA2, with a complete response to first-line treatment with talazoparib, maintained after 6 years. To the best of our knowledge, this is the longest response reported with a PARP inhibitor in a BRCA-mutated tumor. We have made a review of literature, regarding the rationale for PARP inhibitors in carriers of BRCA mutations and their clinical relevance in the management of advanced breast cancer, as well as their emerging role in early stage disease, alone and in combination with other systemic therapies.

【 授权许可】

Unknown   
Copyright © 2023 Albarrán, Chamorro, Pozas, San Román, Rosero, Saavedra, Gion, Cortés, Escalera, Guerra, López Miranda, Fernández Abad and Martínez Jañez